Get the latest news, insights, and market updates on BBNX (Beta Bionics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Beta Bionics receives FDA warning letter
The letter, which the FDA has not yet published, does not affect Beta Bionics’ ability to market, manufacture or distribute products, the company said. Feb 2, 2026 - $BBNX
Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 financial results after the financial markets close on Tuesday, February 17, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s fourth quarter and fu Jan 15, 2026 - $BBNX
Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics
IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results and key metrics for the quarter ended December 31, 2025. Members of the Company’s management team will host in-person meetings in San Francisco, CA from January 12, 2026 through January 14, 2026 to discuss preliminary topline fourth quarter 2025 financial results a Jan 8, 2026 - $BBNX
Is Beta Bionics (BBNX) Overvalued After Its Recent Share Price Momentum?
Beta Bionics (BBNX) has quietly put up a solid run lately, with the stock gaining about 7% over the past month and roughly 27% in the past 3 months, despite ongoing losses. See our latest analysis for Beta Bionics. Zooming out, that recent 30 day and 90 day share price return strength fits into a broader year to date share price return in the mid 20s. This suggests momentum is quietly building as investors reassess Beta Bionics growth potential against its losses. If this kind of early stage... Dec 18, 2025 - $BBNX
Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026
IRVINE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to pre-release its topline fourth quarter 2025 financial results the week of January 5, 2026. Topline financial results covered in the pre-release are expected to include net sales, new patient starts, and the percentage of new patient starts reimbursed through the pharmacy benefit plan Dec 8, 2025 - $BBNX
Beta Bionics Announces Participation at Upcoming Investor Conferences
IRVINE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at two upcoming investor conferences (all Eastern Time): Wolfe Research 7th Annual Healthcare Conference on Tuesday, November 18, 2025 at 2:00pmPiper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 4:30pm The presentations will be webcast live. The link to the w Nov 3, 2025 - $BBNX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple